Article

Potential therapeutic uses of BDNF in neurological and psychiatric disorders.

Center for Neural Repair, Department of Neurosciences 0626, University of California, San Diego, La Jolla, California 92093, USA.
dressNature Reviews Drug Discovery (Impact Factor: 37.23). 03/2011; 10(3):209-19. DOI: 10.1038/nrd3366
Source: PubMed

ABSTRACT The growth factor brain-derived neurotrophic factor (BDNF) and its receptor tropomyosin-related kinase receptor type B (TRKB) are actively produced and trafficked in multiple regions in the adult brain, where they influence neuronal activity, function and survival throughout life. The diverse presence and activity of BDNF suggests a potential role for this molecule in the pathogenesis and treatment of both neurological and psychiatric disorders. This article reviews the current understanding and future directions in BDNF-related research in the central nervous system, with an emphasis on the possible therapeutic application of BDNF in modifying fundamental processes underlying neural disease.

1 Bookmark
 · 
197 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Endocytosis of tropomyosin related kinase B (TrkB) receptors has critical roles in brain-derived neurotrophic factor (BDNF) mediated signal transduction and biological function, however the mechanism that is governing TrkB endocytosis is still not completely understood. In this study, we showed that GSK3β, a key kinase in neuronal development and survival, could regulate TrkB endocytosis through phosphorylating dynamin1 (Dyn1) but not dynamin2 (Dyn2). Moreover, we found that beta-amyloid (Aβ) oligomer exposure could impair BDNF-dependent TrkB endocytosis and Akt activation through enhancing GSK3β activity in cultured hippocampal neurons, which suggested that BDNF-induced TrkB endocytosis and the subsequent signaling were impaired in neuronal model of Alzheimer's disease (AD). Notably, we found that inhibiting GSK3β phosphorylating Dyn1 by using TAT-Dyn1SpS could rescue the impaired TrkB endocytosis and Akt activation upon BDNF stimuli under Aβ exposure. Finally, TAT-Dyn1SpS could facilitate BDNF-mediated neuronal survival and cognitive enhancement in mouse models of AD. These results clarified a role of GSK3β in BDNF-dependent TrkB endocytosis and the subsequent signaling, and provided a potential new strategy by inhibiting GSK3β-induced Dyn1 phosphorylation for AD treatment. Copyright © 2014 Elsevier Inc. All rights reserved.
    Neurobiology of Disease 12/2014; 74C:377-391. · 5.62 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVES: Physical exercise up-regulates brain-derived neurotrophic factor (BDNF) in brain and blood. However, there is yet no consensus about the adequate blood processing conditions to standardize its assessment. We aimed to find a reliable blood sample processing method to determine changes in BDNF due to exercise. DESIGN AND METHODS: Twelve healthy university students performed an incremental cycling test to exhaustion. At baseline, immediately after exercise, and 30 and 60minutes of recovery, venous blood was drawn and processed under different conditions, i.e. whole blood, serum coagulated for 10minutes and 24hours, total plasma, and platelet-free plasma. BDNF concentration was measured by ELISA. RESULTS: Exercise increased BDNF in whole blood and in serum coagulated for 24hours when corrected by hemoconcentration. We did not find effects of exercise on BDNF in serum coagulated for 10minutes or in plasma samples. Plasma shows heterogeneous BDNF values in response to exercise that are not prevented when platelets are eliminated whilst homogeneous BDNF levels were found in whole blood or serum coagulated for 24hours samples. CONCLUSIONS: In exercise studies, BDNF levels should be adjusted by hemoconcentration. Our data highlight the importance of blood sample selection since the differences between each one affect significantly the BDNF factor changes due to exercise.
    Clinical Biochemistry 11/2014; · 2.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Brain-derived neurotrophic factor (BDNF) attracts increasing attention from both research and clinical fields because of its important functions in the central nervous system. An adequate amount of BDNF is critical to develop and maintain normal neuronal circuits in the brain. Given that loss of BDNF function has been reported in the brains of patients with neurodegenerative or psychiatric diseases, understanding basic properties of BDNF and associated intracellular processes is imperative. In this review, we revisit the gene structure, transcription, translation, transport and secretion mechanisms of BDNF. We also introduce implications of BDNF in several brain-related diseases including Alzheimer's disease, Huntington's disease, depression and schizophrenia.
    World journal of biological chemistry. 11/2014; 5(4):409-428.